Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 23:13:957407.
doi: 10.3389/fimmu.2022.957407. eCollection 2022.

Lymphocyte-C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission

Jian-Nan Zhang  1 , Yang Gao  2   3 , Xin-Tong Wang  1 , Na-Na Li  1 , Xue Du  1 , Yu-Jia Tang  1 , Qi-Qi Lai  1 , Peng-Fei Chen  1 , Chuang-Shi Yue  1 , Ji-Han Wu  1 , Kai Kang  1   3 , Ming-Yan Zhao  1
Affiliations

Lymphocyte-C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission

Jian-Nan Zhang et al. Front Immunol. .

Abstract

In this study, we aimed to explore whether lymphocyte-C-reactive protein ratio (LCR) can differentiate disease severity of coronavirus disease 2019 (COVID-19) patients and its value as an assistant screening tool for admission to hospital and intensive care unit (ICU). A total of 184 adult COVID-19 patients from the COVID-19 Treatment Center in Heilongjiang Province at the First Affiliated Hospital of Harbin Medical University between January 2020 and March 2021 were included in this study. Patients were divided into asymptomatic infection group, mild group, moderate group, severe group, and critical group according to the Diagnosis and Treatment of New Coronavirus Pneumonia (ninth edition). Demographic and clinical data including gender, age, comorbidities, severity of COVID-19, white blood cell count (WBC), neutrophil proportion (NEUT%), lymphocyte count (LYMPH), lymphocyte percentage (LYM%), red blood cell distribution width (RDW), platelet (PLT), C-reactive protein (CRP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (SCr), albumin (ALB), total bilirubin (TB), direct bilirubin (DBIL), indirect bilirubin (IBIL), and D-dimer were obtained and collated from medical records at admission, from which sequential organ failure assessment (SOFA) score and LCR were calculated, and all the above indicators were compared among the groups. Multiple clinical parameters, including LYMPH, CRP, and LCR, showed significant differences among the groups. The related factors to classify COVID-19 patients into moderate, severe, and critical groups included age, number of comorbidities, WBC, LCR, and AST. Among these factors, the number of comorbidities showed the greatest effect, and only WBC and LCR were protective factors. The area under the receiver operating characteristic (ROC) curve of LCR to classify COVID-19 patients into moderate, severe, and critical groups was 0.176. The cutoff value of LCR and the sensitivity and specificity of the ROC curve were 1,780.7050 and 84.6% and 66.2%, respectively. The related factors to classify COVID-19 patients into severe and critical groups included the number of comorbidities, PLT, LCR, and SOFA score. Among these factors, SOFA score showed the greatest effect, and LCR was the only protective factor. The area under the ROC curve of LCR to classify COVID-19 patients into severe and critical groups was 0.106. The cutoff value of LCR and the sensitivity and specificity of the ROC curve were 571.2200 and 81.3% and 90.0%, respectively. In summary, LCR can differentiate disease severity of COVID-19 patients and serve as a simple and objective assistant screening tool for hospital and ICU admission.

Keywords: COVID-19; ICU admission; SARS-CoV-2 infection; disease severity; hospital admission; lymphocyte–C-reactive protein ratio; screening tool.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of the study participants.
Figure 2
Figure 2
The receiver operating characteristic (ROC) curve of LCR to classify COVID-19 patients into moderate, severe, and critical groups.
Figure 3
Figure 3
The receiver operating characteristic (ROC) curve of LCR to classify COVID-19 patients into severe and critical groups.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chen Q, Gao Y, Wang CS, Kang K, Yu H, Zhao MY, et al. . Exploration of transmission chain and prevention of the recurrence of coronavirus disease 2019 in heilongjiang province due to in-hospital transmission. World J Clin cases (2021) 9:5420–6. doi: 10.12998/wjcc.v9.i20.5420 - DOI - PMC - PubMed
    1. Saito A, Irie T, Suzuki R, Maemura T, Nasser H, Uriu K, et al. . Enhanced fusogenicity and pathogenicity of SARS-CoV-2 delta P681R mutation. Nature (2022) 602:300–6. doi: 10.1038/s41586-021-04266-9 - DOI - PMC - PubMed
    1. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. . The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet (2021) 22:757–73. doi: 10.1038/s41576-021-00408-x - DOI - PMC - PubMed
    1. Meo SA, Meo AS, Al-Jassir FF, Klonoff DC. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci (2021) 25:8012–8. doi: 10.26355/eurrev_202112_27652 - DOI - PubMed
    1. Chen J, Wang R, Wang M, Wei GW. Mutations strengthened SARS-CoV-2 infectivity. J Mol Biol (2020) 432:5212–26. doi: 10.1016/j.jmb.2020.07.009 - DOI - PMC - PubMed

Publication types